You are viewing: Turkey Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The Turkey Plasma Fractionation Market was valued at $178.2 Million in 2026 and projected to reach to $222.8 Million by 2031, representing a compound annual growth rate of 4.6%. Turkey's plasma fractionation market is positioned for steady growth driven by expanding healthcare infrastructure and increasing awareness of plasma-derived therapies.

Turkey Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Turkey Plasma Fractionation Market Trends and Insights

  • Turkey's healthcare infrastructure continues to expand, driving demand for plasma-derived therapies and immunoglobulin products.
  • The market in Turkey is supported by increasing prevalence of bleeding disorders, immunodeficiencies, and chronic diseases requiring plasma fractionation treatments. Turkey's plasma fractionation sector benefits from rising healthcare expenditure and improved patient access to advanced therapeutic options.
  • Between 2026 and 2031, Turkey is expected to see steady growth driven by demographic shifts, enhanced diagnostic capabilities, and greater awareness of plasma-derived medicines.
  • Turkey's position as a regional healthcare hub strengthens its market potential for plasma fractionation products and services. The regulatory environment in Turkey continues to evolve, supporting the introduction of new plasma fractionation therapies.
  • Turkey's market growth reflects broader trends in emerging healthcare markets, where demand for specialized blood products and immunotherapies is accelerating..

Key Market Statistics

  • CAGR (2026-2031) 4.6% CAGR
  • Market Size, 2026 ~USD 178.2 Million
  • Forecast, 2031 ~USD 222.8 Million
  • Country Turkey

Turkey Plasma Fractionation Market Overview

Market Valuation Growth :

Turkey's plasma fractionation market is valued at USD 178.2 million in 2026 and is projected to reach USD 222.8 million by 2031, demonstrating steady expansion in the healthcare sector.

Rising Bleeding Disorder Prevalence :

Increasing prevalence of bleeding disorders and hemophilia in Turkey is driving demand for plasma-derived therapies, creating sustained market opportunities for fractionation products.

Healthcare Infrastructure Expansion :

Turkey's growing healthcare infrastructure and improved access to specialized medical facilities are enhancing the availability and adoption of immunoglobulin products and plasma therapies.

Moderate Growth Trajectory :

With a CAGR of 4.6% through 2031, Turkey's market demonstrates consistent growth, though at a slower pace than the global market's 7.6% CAGR, reflecting regional market maturation.

Turkey Plasma Fractionation Market Dynamics

  • The rising prevalence of bleeding disorders and immunodeficiency conditions continues to fuel demand for immunoglobulin products and clotting factor concentrates.
  • Government initiatives to strengthen healthcare delivery and improve patient access to specialized treatments are supporting market expansion.
  • However, regulatory challenges and pricing pressures may moderate growth rates compared to global benchmarks.
  • Strategic investments in plasma collection centers and manufacturing capabilities will be critical for market players seeking to capitalize on Turkey's growing patient population and healthcare modernization efforts..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • Turkey's plasma fractionation market is projected to grow from USD 178.2 million in 2026 to USD 222.8 million in 2031 at a 4.6% CAGR.
      • Turkey's expanding healthcare infrastructure and rising disease prevalence are key drivers of plasma fractionation market growth.
      • Turkey benefits from increasing healthcare expenditure and improved access to plasma-derived therapies across the region.
      • Turkey's regulatory environment is evolving to support the introduction and adoption of advanced plasma fractionation products.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      Turkey Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Pharmaceutical & Biotech Companies : Manufacturers and distributors of plasma-derived therapies need Turkey-specific market data to assess market size, growth potential, and competitive positioning for product launches and portfolio expansion.
      • Healthcare Investment Firms : Private equity and venture capital investors require detailed Turkey market analysis to evaluate investment opportunities in plasma fractionation companies, collection centers, and healthcare infrastructure.
      • Hospital & Clinical Networks : Turkish healthcare providers and hospital networks need market insights to understand plasma product demand, procurement strategies, and supply chain optimization for patient care delivery.
      • Government & Regulatory Bodies : Turkish health ministry officials and regulatory agencies require market intelligence to inform healthcare policy, plasma collection standards, and reimbursement frameworks for fractionation products.
      • Market Research & Consulting Firms : Research organizations and consultants need comprehensive Turkey market data to support client advisory services, competitive analysis, and strategic planning in the plasma fractionation sector.

      Reasons to Buy this Report

      • Country-Specific Market Sizing : Obtain precise valuation data for Turkey's plasma fractionation market with verified 2026-2031 forecasts, enabling accurate budget allocation and investment planning for regional operations.
      • Competitive Landscape Intelligence : Understand Turkey-specific market dynamics, local competitor positioning, and regulatory environment to develop targeted market entry or expansion strategies in this emerging healthcare market.
      • Disease Prevalence Insights : Access detailed analysis of bleeding disorder and immunodeficiency prevalence in Turkey, identifying patient populations and clinical demand drivers for plasma-derived products.
      • Healthcare Infrastructure Assessment : Evaluate Turkey's expanding healthcare infrastructure, plasma collection capabilities, and distribution networks to identify partnership opportunities and market penetration strategies.
      • Growth Opportunity Identification : Leverage Turkey-focused forecasts and market trends to identify high-potential segments, unmet clinical needs, and emerging opportunities within the 4.6% CAGR growth trajectory.

      Frequently asked questions

      What is the current size of Turkey's plasma fractionation market?

      Turkey's plasma fractionation market is valued at USD 178.2 million in 2026.

      What is the projected market size for Turkey's plasma fractionation sector by 2031?

      Turkey's plasma fractionation market is forecast to reach USD 222.8 million by 2031.

      What is the CAGR for Turkey's plasma fractionation market?

      Turkey's plasma fractionation market is expected to grow at a CAGR of 4.6% between 2026 and 2031.

      What factors are driving growth in Turkey's plasma fractionation market?

      Growth in Turkey's market is driven by expanding healthcare infrastructure, rising disease prevalence, increased healthcare expenditure, and improved patient access to plasma-derived therapies.

      How does Turkey's plasma fractionation market compare to global trends?

      Turkey's 4.6% CAGR reflects steady growth in an emerging market, supported by regional healthcare development and increasing demand for specialized blood products.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status